Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT02954809
Official study title

Feasibility of Bright Light Therapy on Fatigue, Sleep and Circadian Activity Rhythms in Lung Cancer Survivors

Study summary

The purpose of this study is to determine the feasibility of a morning bright light therapy intervention for fatigue, sleep disturbances, and circadian activity rhythms in lung cancer survivors.

Ask AI to explain this study
Start here

Key things to know

Main goalDevice Feasibility

This describes the study’s primary purpose.

What is being studiedMorning bright light therapy and Dim light

The study team can explain what participation involves.

Who it may be forFatigue · Sleep Disturbance

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 1, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?State University of New York at Buffalo

Study sponsor

01
Study overview

What this study is about

Purpose
Device Feasibility
Study type
Interventional
Phase
Not applicable
Sponsor
State University of New York at Buffalo
Interventions being studied
Device: Morning bright light therapy; Device: Dim light
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Stage I-III Non-small cell lung cancer survivors
  • Must be at \>6-weeks and \< 3 years post-surgical resection
  • Must have diagnosis fatigue and/or sleep disturbances
Reasons someone may not be able to joinExclusion criteria
  • Individuals clinically unstable.
  • Mania, Bipolar disease or seizure disorder
  • Macular degeneration or glaucoma.
  • Currently receiving chemotherapy or radiation.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • SUNY University at BuffaloBuffalo, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 1, 2025. Always confirm current availability with the study team.

View original record ↗